Hyperhomocysteinemia and Its Treatment in Patients with Ischemic Stroke

Abstract

Homocistein je metabolit nastao u procesu demetilacije metionina. Ima proaterogeno, protrombotsko, prooksidativno, proapoptotsko, neurotoksično, neuroinflamatorno i neurodegenerativno djelovanje. Hiperhomocisteinemija je povezana s postojanjem mutacije C667T MTHFR, sniženjem razine folne kiseline i vitamina B-grupe, ali i s dugotrajnim uzimanjem nekih lijekova. Provedeno je istraživanje u Klinici za neurologiju Univerzitetskoga kliničkog centra u Tuzli. Mjerene su razine homocisteina u šezdeset ispitanika obaju spolova u akutnoj fazi ishemijskog cerebrovaskularnog inzulta, a potom su praćeni efekti medikamentnog pristupa (folna kiselina, vitamini B-grupe) šestomjesečno u sljedeće tri godine. Hiperhomocisteinemija je bila prisutna u 16,67% bolesnika, a prosječna razina bila je viša u pacijenata muškog spola (p=0,073). Svaki treći oboljeli muškarac (33,3%) imao je povišene razine (p < 0,001), dok u bolesnica nije uočena hiperhomocisteinemija. Prilikom unosa folne kiseline u dnevnoj dozi od 5 mg peroralnim putem razine homocisteina bile su normalizirane u svih, ali su nekima dodatno ordinirani i vitamini B-grupe.Homocysteine is a metabolite of methionine demethylation. It has proatherogenic, prothrombotic, prooxidative, proapoptotic, neurotoxic, neuroinflammatory and neurodegenerative effects. Hyperhomocysteinemia correlates with C667T MTHFR mutation, decreased folic acid and vitamin B levels, and prolonged use of certain medications. We measured homocysteine levels in sixty patients at the Department of Neurology of the University Clinical Centre Tuzla and monitored the effects of medicaments (folic acid, vitamin B) every six months over a three-year period. In acute phase of ischemic stroke, hyperhomocysteinemia was present in 16.67% of patients. The average level was higher in male patients (p=0.073). Higher than normal homocysteine levels were recorded in every third male patient (33.3%) (p<0.001). Hyperhomocysteinemia was not observed in women with ischemic stroke. The oral administration of 5 mg folic acid per day normalized homocysteine levels in all patients, but some also received vitamin B

    Similar works